Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma.
Xiao G, Li L, Tanzhu G, Liu Z, Gao X, Wan X, Xiao D, Chen L, Xia X, Zhou R.
J Immunother Cancer. 2023 Mar;11(3):e006243. doi: 10.1136/jitc-2022-006243.
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
Ricciuti B, Fusco F, Cooper A, Garbo E, Pecci F, Aldea M, Wang X, Mayoral Penalva M, Ginsberg M, Sholl LM, Nishino M, Di Federico A, Shaverdian N, Bott M, Santo V, Rendina E, Trisolini R, Ramella S, Gallina F, Melis E, Buglioni S, Minuti G, Landi L, Ugalde Figueroa PA, Shaw AT, Chaft J, Awad MM, Cappuzzo F.
JAMA Oncol. 2025 Jul 1;11(7):735-741. doi: 10.1001/jamaoncol.2025.1115.
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study.
Bahce I, Dickhoff C, Schneiders FL, Veltman J, Heineman DJ, Hashemi SMS, Vrijmoet A, Houda I, Ulas EB, Bakker J, van de Ven P, Bouwhuis N, Meijboom LJ, Oprea-Lager DE, van Maldegem F, Fransen MF, de Gruijl TD, Radonic T, Senan S.
J Immunother Cancer. 2024 Sep 30;12(9):e009799. doi: 10.1136/jitc-2024-009799.
Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms.
Ferencz B, Török K, Pipek O, Fillinger J, Csende K, Lantos A, Černeková R, Mitták M, Škarda J, Delongová P, Megyesfalvi E, Schelch K, Lang C, Solta A, Boettiger K, Brcic L, Lindenmann J, Rényi-Vámos F, Aigner C, Berta J, Megyesfalvi Z, Döme B.
Cancer Immunol Immunother. 2024 May 2;73(6):114. doi: 10.1007/s00262-024-03704-7.
Inflammatory myofibroblastic tumor of the lung in children: anaplastic lymphoma kinase (ALK) expression and clinico-pathological correlation.
Siminovich M, Galluzzo L, López J, Lubieniecki F, de Dávila MT.
Pediatr Dev Pathol. 2012 May-Jun;15(3):179-86. doi: 10.2350/11-10-1105-OA.1. Epub 2012 Jan 26.
Controversies in the management of stage III non-small-cell lung cancer.
Biswas T, Sharma N, Machtay M.
Expert Rev Anticancer Ther. 2014 Mar;14(3):333-47. doi: 10.1586/14737140.2014.867809. Epub 2014 Jan 8.
Parity and risk of lung cancer in women: systematic review and meta-analysis of epidemiological studies.
Dahabreh IJ, Trikalinos TA, Paulus JK.
Lung Cancer. 2012 May;76(2):150-8. doi: 10.1016/j.lungcan.2011.10.014. Epub 2011 Dec 9.
Prognostic impact of underlying lung disease in pulmonary wedge resection for lung cancer.
Kawaguchi T, Sawabata N, Miura S, Kawai N, Yasukawa M, Tojo T, Taniguchi S.
Int J Clin Oncol. 2019 Apr;24(4):366-374. doi: 10.1007/s10147-018-1367-3. Epub 2018 Nov 15.
Distribution of VRA09, an ovarian tumor-associated antigen, distinguishing borderline serous tumors.
Voeltzel T, Duvillard P, Ghillani P, Bénard J, Bohuon C, Bellet D, Bidart JM.
Int J Cancer. 1994 Oct 15;59(2):159-64. doi: 10.1002/ijc.2910590203.
Rapid imaging of lung cancer using a red fluorescent probe to detect dipeptidyl peptidase 4 and puromycin-sensitive aminopeptidase activities.
Kawashima S, Yoshida D, Yoshioka T, Ogasawara A, Fujita K, Yanagiya M, Nagano M, Konoeda C, Hino H, Kitano K, Sato M, Hino R, Kojima R, Komatsu T, Kamiya M, Urano Y, Nakajima J.
Sci Rep. 2022 Jun 1;12(1):9100. doi: 10.1038/s41598-022-12665-9.
